Therapies against viral infections.
The Atriva Approach
First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.
Great potential against a wide variety of respiratory viruses due to immunomodulating and antiviral activity of ATRIVA’s lead product zapnometinib (INN). Phase I clinical trial successfully completed, RESPIRE (a Phase II clinical trial in COVID-19) started patient enrollment in April 2021. A Phase II study in influenza is currently planned.